{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:24:11Z","timestamp":1790796251264,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1053\/j.ajkd.2017.08.008","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T05:46:23Z","timestamp":1511243183000},"page":"142-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report"],"prefix":"10.1053","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6740-3961","authenticated-orcid":false,"given":"Elodie","family":"Bailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Von Tokarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Beau-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Picon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Miquelestorena-Standley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie-Pierre","family":"Jonville-Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.ajkd.2017.08.008_bib1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"8","key":"10.1053\/j.ajkd.2017.08.008_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohns disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2017.08.008_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"issue":"2","key":"10.1053\/j.ajkd.2017.08.008_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2215\/CJN.04660513","article-title":"The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease","volume":"9","author":"Ambruzs","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2017.08.008_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ecco-jcc\/jjv219","article-title":"Clinical features and HLA\u00a0association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease","volume":"10","author":"Heap","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"1","key":"10.1053\/j.ajkd.2017.08.008_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/qjmed\/hcp146","article-title":"Acute renal failure from nitrofurantoin-induced acute granulomatous interstitial nephritis","volume":"103","author":"Namagondlu","year":"2010","journal-title":"QJM"},{"issue":"5","key":"10.1053\/j.ajkd.2017.08.008_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"issue":"2","key":"10.1053\/j.ajkd.2017.08.008_bib8","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1523-1755.2001.060002804.x","article-title":"Drug-induced acute interstitial nephritis","volume":"60","author":"Rossert","year":"2001","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2017.08.008_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4081\/nr.2013.e4","article-title":"Acute interstitial nephritis: etiology, pathogenesis, diagnosis, treatment and prognosis","volume":"5","author":"Sathick","year":"2013","journal-title":"Nephrol Rev"},{"issue":"4","key":"10.1053\/j.ajkd.2017.08.008_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1345\/aph.1H635","article-title":"Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma","volume":"41","author":"Barakat","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1053\/j.ajkd.2017.08.008_bib11","article-title":"Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme","volume":"19","author":"Lomax","year":"2013","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"5","key":"10.1053\/j.ajkd.2017.08.008_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4166\/kjg.2014.63.5.308","article-title":"A\u00a0case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn\u2019s disease","volume":"63","author":"Yoo","year":"2014","journal-title":"Korean J Gastroenterol"},{"issue":"5","key":"10.1053\/j.ajkd.2017.08.008_bib13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.1780360523","article-title":"Treatment with anti-CD4 monoclonal antibody and acute interstitial nephritis","volume":"36","author":"Choy","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ajkd.2017.08.008_bib14","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"issue":"6","key":"10.1053\/j.ajkd.2017.08.008_bib15","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1053\/j.ajkd.2010.08.019","article-title":"Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab","volume":"56","author":"Korsten","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2017.08.008_bib16","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2017.08.008_bib17","first-page":"89","article-title":"Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma","volume":"35","author":"Weber","year":"2012","journal-title":"J\u00a0Immunother"},{"issue":"2","key":"10.1053\/j.ajkd.2017.08.008_bib18","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"issue":"9","key":"10.1053\/j.ajkd.2017.08.008_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","article-title":"Paradoxical inflammation induced by anti-TNF agents in patients with IBD","volume":"9","author":"Cleynen","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1053\/j.ajkd.2017.08.008_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0953-6205(03)00078-5","article-title":"Sarcoidosis and interferon therapy: report of five cases and review of the literature","volume":"14","author":"Leclerc","year":"2003","journal-title":"Eur J Intern Med"},{"key":"10.1053\/j.ajkd.2017.08.008_bib21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-\u03b14\u03b27 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"6","key":"10.1053\/j.ajkd.2017.08.008_bib22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4161\/mabs.26392","article-title":"In\u00a0vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes","volume":"5","author":"Wyant","year":"2013","journal-title":"MAbs"},{"issue":"11","key":"10.1053\/j.ajkd.2017.08.008_bib23","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14 \u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617309034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617309034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:00:52Z","timestamp":1759460452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617309034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0272638617309034"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.08.008","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}